Blood
Articles in this Issue
It’s high TIM-3 for armored CAR-T therapy for B-ALL
HLA antibodies delay platelet recovery after gene therapy
Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study
Abstract The non-O blood group is a well-established risk factor for venous thromboembolism (VTE). However, the association between plasma levels of the histo–blood group ABO system...
Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia
Abstract We report our single-center experience demonstrating that HLA class I alloimmunization predicts longer time to platelet engraftment, increased bleeding complications, and hi...
Guidance on the interpretation of CRBN mutations in myeloma
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Abstract “Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized...
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
Abstract Venetoclax (VEN) combined with hypomethylating agents is approved for frontline therapy in older/unfit patients with acute myeloid leukemia (AML). However, prospective data...
I+Ve got a question: how long should we treat relapsed CLL?
Exploring the ABO-VTE connection
Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow
Precision medicine for high-risk gene fusions in pediatric AML: a focus on <i>KMT2A</i>, <i>NUP98</i>, and <i>GLIS2</i> rearrangements
Abstract Robust genetic characterization of pediatric acute myeloid leukemia (AML) has demonstrated that fusion oncogenes are highly prevalent drivers of AML leukemogenesis in young...
Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma
Abstract Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the gen...
“Scotty, we need more power!”
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial
Abstract The combination of ibrutinib plus venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment leverages their complementary mechanisms of action. Studies investigating I...
Are you ready for it? VEN-HMA for younger patients with AML
A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia
Abstract Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-direct...
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them
Abstract Leukopoiesis is lethally arrested in mice lacking the master transcriptional regulator PU.1. Depending on the animal model, subtotal PU.1 loss either induces acute myeloid l...
SPI-ing on human B-cell development
Evaluating the impact of <i>CRBN</i> mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
Abstract Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggest almost one-third of myeloma patients acquire genetic alterati...